Search This Blog

Wednesday, June 10, 2015

Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis (NYSE:LLY)

EULAR congress in Rome will be first public presentations of Phase 3 data



Lilly and Incyte unveil detailed data on two pivotal studies of baricitinib in rheumatoid arthritis (NYSE:LLY)

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.